Becton, Dickinson stock
Price history
+43.67% over the period1 year: from $151.76 (November 13, 2025) to $218.03 (November 13, 2026), +43.67%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $218.03 |
| October 30, 2026 | $197.88 |
| September 30, 2026 | $179.00 |
| August 31, 2026 | $188.11 |
| July 31, 2026 | $165.62 |
| June 30, 2026 | $151.33 |
| May 29, 2026 | $147.12 |
| April 30, 2026 | $149.04 |
| March 31, 2026 | $157.23 |
| February 27, 2026 | $176.48 |
| January 30, 2026 | $159.97 |
| December 31, 2025 | $152.57 |
| November 28, 2025 | $152.53 |
| November 13, 2025 | $151.76 |
At a glance
The company
Makes medical devices, supplies, lab equipment and diagnostic products for healthcare providers, researchers and labs worldwide
Latest results
Quarter to September 30, 2026 · EPS $4.15 (estimate $4.07)
Dividend
TickerLandia's take on Becton, Dickinson
- Pricier than usual relative to earnings: P/E on the latest fiscal year 37 vs a median of 32 over its last 9 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 43 vs 43 (+0%) in a group of 9.
- Strong point: Market momentum (92/100 in its group). Weak point: Financial strength (23/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.80% from the 52-week high
Analysts · 16 analysts
Average target$226.14+3.72% vs. price
Buy 9 · Hold 6 · Sell 1 · Buy
TickerLandia Fingerprint: Becton, Dickinson
Compared with similar companies: very strong momentum, very high dividend, and very high earnings stability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow39
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 3.05 51 Forward P/E 15.3 22 P/E (trailing 12 months) 43.1 58 EV/EBITDA 14.2 34 Price/book 2.41 31 Profitabilitylow36
How much it earns on revenue and capital.
Metric Value Position in group ROA 3.6% 31 Gross margin 47.0% 40 Net margin 5.9% 31 ROE 5.7% 25 Operating margin 15.7% 51 Earnings stabilityvery high81
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.5% 99 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthlow33
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +4.99% 40 Earnings growth (year over year) +47.60% 56 Revenue growth (year over year) −10.50% 4 Financial strengthlow23
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 5.97 38 Debt/equitycounts in reverse: lower means more financial strength 0.66 29 Current ratio 0.87 7 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.16 17 Dividendvery high84
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.9% 72 Consecutive dividend years at least 37 years 94 Payout ratio 83.0% 85 Market momentumvery strong92
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +48.87% 94 Distance from 200-day average +29.40% 96 1-year return +43.67% 84 Relative strength (3 months) +23.58% 94 Risklow30
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 24.1% 38 Volatility (60 days) 24.0% 22 Beta (1 year) 0.27 30
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Becton, Dickinson is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Becton, Dickinson's P/E today is 37.5, above the median of its last 9 fiscal years (32.3; between 25.3 and 65.9 from 2016 to 2025). Becton, Dickinson's P/E (trailing 12 months): 43.1, in line with the median of a group of 9 similar companies (43.1).
Compared with 9 similar companies
| Metric | Becton, Dickinson | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 43.1 | Middle | |
| Forward P/E | 15.3 | Middle | |
| Operating margin | 15.7% | Middle | |
| ROE | 5.7% | Middle | |
| Debt/equity | 0.66 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Becton, Dickinson. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$4.98B
Latest quarter · Q2 2026
Net income
$377M
Latest quarter · Q2 2026
Quarterly net margin
7.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $59.39B
- P/E
- 43.1
- EPS
- $5.06
- Volume
- 1.88M
- Daily trading
- €363.61M
- Dividend yield
- 1.93%
How Becton, Dickinson is changing
All resultsRevenue grew 6.3% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 161% of net income
Revenue has grown for 3 fiscal years in a row
Returns
Becton, Dickinson returns with dividends
$1,000 invested in Becton, Dickinson 5 years ago, on November 15, 2021, would be worth $1,301 today with dividends reinvested: +30.06% in total, +5.40% per year. On price alone it would be $1,167 (+16.66%).
| Period | Becton, Dickinson | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +16.36% | −3.12% | $1,164 |
| 6 months | +51.22% | +1.58% | $1,512 |
| Year to date | +42.90% | +10.46% | $1,429 |
| 1 year | +47.47% | +12.23% | $1,475 |
| 3 years | +26.45% | +71.41% | $1,265 |
| 5 years | +30.06% | +61.48% | $1,301 |
| 10 years | +108.35% | +249.40% | $2,083 |
Over the last 6 months it has done better than 87% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Becton, Dickinson: technical analysis
Becton, Dickinson is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 2.2% below its highest close since January 2, 1990 ($222.95, July 27, 2023).
- Trend
- Upward
- RSI (14 sessions)
- 76
- Above 70: a strong rise in a short time
- vs 200-session average
- +29.40%
Active signals
New 52-week high.
since November 12, 2026
Close above the high of the previous 55 sessions.
RSI above 70: the stock has risen a lot in a short time.
since November 4, 2026
Support and resistance
Price areas where Becton, Dickinson has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$218.03
- Support$192.42−11.75%2 touches, last on September 2, 2026
- Support$186.99−14.24%2 touches, last on September 15, 2026
- Support$175.46−19.53%2 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.27
- Volatility (60 sessions, annualised)
- 24.0%
- Largest fall in the last year
- −24.10%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Becton, Dickinson: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Becton, Dickinson has been January: +3.94% on average, positive in 23 years out of 36. The weakest has been April: −0.15% on average, positive in 18 years out of 37. November, the current month, has been positive in 25 years out of 36 (+2.25% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.94% | +4.02% | 23 of 36 |
| February | +0.36% | +0.79% | 19 of 37 |
| March | +0.47% | +0.69% | 22 of 37 |
| April | −0.15% | −0.35% | 18 of 37 |
| May | +1.16% | +1.16% | 19 of 37 |
| June | +0.36% | +0.81% | 23 of 37 |
| July | +0.50% | +2.50% | 24 of 37 |
| August | +0.45% | +0.69% | 23 of 37 |
| September | +0.14% | −0.38% | 14 of 37 |
| October | +0.90% | +1.20% | 20 of 37 |
| November | +2.25% | +2.01% | 25 of 36 |
| December | +2.05% | +1.99% | 27 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Becton, Dickinson and its competitors
Hospitals, clinics, physicians, pharmaceutical companies, clinical laboratories and life science researchers form the core customer base of this medical technology group, which also sells to the general public in markets across the world. Its offering ranges from intravenous catheters, vascular access devices, syringes and needles to drug delivery and infusion systems, pharmacy automation software and hemodynamic monitoring.
- Headquarters
- Franklin Lakes, United States
- Employees
- 60,000
- Founded
- 1897
- Chief executive
- Thomas Polen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Becton, DickinsonBDX | $59.39B | 15.7% | 43.1 | +51.22% |
| MedlineMDLN | $51.94B | 5.4% | 89.7 | +1.96% |
| ResMedRMD | $33.69B | 34.0% | 21.8 | +18.36% |
| West Pharmaceutical ServicesWST | $29.01B | 22.9% | 46.7 | +37.71% |
| Intuitive SurgicalISRG | $153.77B | 31.7% | 53.6 | +2.62% |
| SolventumSOLV | $15.14B | 5.9% | 100.1 | +19.72% |
Same industry or related industries, similar size. Compare Becton, Dickinson with its competitors · Full profile
